Journal ArticleDOI
Acute and Longer- Term Outcomes in Depressed Outpatients Requiring One or Several Treatment Steps: A STAR*D Report
A. John Rush,Madhukar H. Trivedi,Stephen R. Wisniewski,Andrew A. Nierenberg,Jonathan W. Stewart,Diane Warden,George Niederehe,Michael E. Thase,Philip W. Lavori,Barry D. Lebowitz,Patrick J. McGrath,Jerrold F. Rosenbaum,Harold A. Sackeim,David J. Kupfer,James F. Luther,Maurizio Fava +15 more
Reads0
Chats0
TLDR
The acute and longer-term treatment outcomes associated with each of four successive steps in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial are described and compared.Abstract:
Objective: This report describes the participants and compares the acute and longer-term treatment outcomes associated with each of four successive steps in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial. Method: A broadly representative adult outpatient sample with nonpsychotic major depressive disorder received one (N=3,671) to four (N=123) successive acute treatment steps. Those not achieving remission with or unable to tolerate a treatment step were encouraged to move to the next step. Those with an acceptable benefit, preferably symptom remission, from any particular step could enter a 12-month naturalistic follow-up phase. A score of ≤5 on the Quick Inventory of Depressive Symptomatology–Self-Report (QIDS-SR 16 ) (equivalent to ≤7 on the 17-item Hamilton Rating Scale for Depression [HRSD 17 ]) defined remission; a QIDS-SR 16 total score of ≥11 (HRSD 17 ≥14) defined relapse. Results: The QIDS-SR 16 remission rates were 36.8%, 30.6%, 13.7%, and 13.0% for the first, second, t...read more
Citations
More filters
Journal ArticleDOI
Modulation of Limbic and Prefrontal Connectivity by Electroconvulsive Therapy in Treatment-resistant Depression: A Preliminary Study
Marta Cano,Marta Cano,Narcís Cardoner,Mikel Urretavizcaya,Mikel Urretavizcaya,Mikel Urretavizcaya,Ignacio Martínez-Zalacaín,Ximena Goldberg,Ximena Goldberg,Esther Via,Esther Via,Oren Contreras-Rodríguez,Oren Contreras-Rodríguez,Joan A. Camprodon,Aida de Arriba-Arnau,Rosa Hernández-Ribas,Rosa Hernández-Ribas,Rosa Hernández-Ribas,Jesús Pujol,Carles Soriano-Mas,Carles Soriano-Mas,Carles Soriano-Mas,José M. Menchón,José M. Menchón,José M. Menchón +24 more
TL;DR: The data support that treatment response involves sequential changes in FC within regions of the intralimbic and limbic-prefrontal networks.
Journal ArticleDOI
Utility of event-related potentials in predicting antidepressant treatment response: An iSPOT-D report
Rik van Dinteren,Martijn Arns,J. Leon Kenemans,Marijtje L.A. Jongsma,Roy P. C. Kessels,Paul B. Fitzgerald,Kamran Fallahpour,Charles DeBattista,Evian Gordon,Leanne M. Williams,Leanne M. Williams +10 more
TL;DR: Differences in the P3 and N1 component from the event-related potential (ERP) generated in a standard two-tone oddball paradigm are investigated and a reduced P3 was found in MDD patients compared to controls by a peak-picking analysis.
Journal ArticleDOI
A randomized, sham-controlled study of maintenance rTMS for treatment-resistant depression (TRD).
René Benadhira,Fanny Thomas,Noomane Bouaziz,Sonia Braha,Palmyre Schenin-King Andrianisaina,Clémence Isaac,Virginie Moulier,Dominique Januel +7 more
TL;DR: Repetitive TMS could represent a novel strategy for preventing relapse in TRD patients who respond to rTMS treatment and should be confirmed in a larger sample.
Journal ArticleDOI
Venlafaxine pharmacokinetics focused on drug metabolism and potential biomarkers
TL;DR: This review provides an extensive discussion of the pharmacokinetics of VEN focusing in particular on metabolism issues, without forgetting the clinically relevant sources of pharmacokinetic variability and aiming on the identification of phenotypic and/or genetic biomarkers for therapy optimization.
Journal ArticleDOI
Negative association of concomitant physical symptoms with the course of major depressive disorder: a systematic review
Klaas M.L. Huijbregts,Christina M. van der Feltz-Cornelis,Christina M. van der Feltz-Cornelis,Harm W.J. van Marwijk,Fransina J. de Jong,Daniëlle A W M van der Windt,Daniëlle A W M van der Windt,Aartjan T.F. Beekman +7 more
TL;DR: A systematic review of major depressive disorder studies shows a negative association of concomitant physical symptoms with the course of MDD, but the number of studies addressing this topic is small and there was a wide variation in the study designs and outcome measures.
References
More filters
Journal ArticleDOI
Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice
Madhukar H. Trivedi,A. John Rush,Stephen R. Wisniewski,Andrew A. Nierenberg,Diane Warden,Louise Ritz,Grayson Norquist,Robert H Howland,Barry D. Lebowitz,Patrick J. McGrath,Kathy Shores-Wilson,Melanie M. Biggs,Goundappa K. Balasubramani,Maurizio Fava +13 more
TL;DR: The response and remission rates in this highly generalizable sample with substantial axis I and axis III comorbidity closely resemble those seen in 8-week efficacy trials.
Journal ArticleDOI
The 16-Item Quick Inventory of Depressive Symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression.
A. John Rush,Madhukar H. Trivedi,Hicham M. Ibrahim,Thomas J. Carmody,Bruce A. Arnow,Daniel N. Klein,John C. Markowitz,Philip T. Ninan,Susan G. Kornstein,Rachel Manber,Michael E. Thase,James H. Kocsis,Martin B. Keller +12 more
TL;DR: The QIDS-SR(16) has highly acceptable psychometric properties, which supports the usefulness of this brief rating of depressive symptom severity in both clinical and research settings.
Journal ArticleDOI
Cross-Validation of Item Selection and Scoring for the SF-12 Health Survey in Nine Countries: Results from the IQOLA Project
Barbara Gandek,John E. Ware,Neil K. Aaronson,Giovanni Apolone,Jakob B. Bjorner,John Brazier,Monika Bullinger,Stein Kaasa,Alain Leplège,Luis Prieto,Marianne Sullivan +10 more
TL;DR: In this article, the authors compared the SF-12 and SF-36 summary measures in nine European countries (Denmark, France, Germany, Italy, Netherlands, Norway, Spain, Sweden, and the United Kingdom).
Journal ArticleDOI
Cumulative illness rating scale.
TL;DR: A Cumulative Illness Rating Scale, designed to meet the need for a brief, comprehensive and reliable instrument for assessing physical impairment, has been developed and tested and is well suited to a variety of research uses.
Journal ArticleDOI
The Inventory of Depressive Symptomatology (IDS): Psychometric properties.
TL;DR: Analysis of sensitivity to change in symptom severity in an open-label trial of fluoxetine showed that the IDs-C and IDS-SR were highly related to the 17-item Hamilton Rating Scale for Depression.